← Back to search

Sensible Biotechnologies

Unlocking the next generation of mRNA medicines

Y CombinatorSummer 2021ActiveHealthcareTherapeuticsSynthetic BiologyBiotechManufacturingTherapeutics

What they do

Problem

mRNA therapeutics are limited by manufacturing challenges that prevent scalable, stable, cost-effective production.

Solution

They use living cells as factories to produce abundant, highly stable, non-immunogenic mRNA at scale and lower cost.

Who it's for

Biopharma companies and therapeutic developers manufacturing mRNA-based medicines.

Founders

Miroslav Gasparek

Founder

I am Miro, CEO and Co-Founder of Sensible Biotechnologies. We build a cell-based platform for cost-efficient and scalable production of high-quality mRNA to unlock next generation of mRNA medicines. My background is in computational modeling of biological systems and bioengineering. I have worked on developing Slovak national biosecurity policies - I am passionate about building biotech ecosystem in Eastern Europe. I studied Bioengineering at Imperial College London and Engineering at Oxford.

LinkedIn · X

Marian Kupculak

Founder

I am Marian, the Chief Scientific Officer and co-founder of Sensible Biotechnologies. We are building a new platform for cost-efficient and scalable manufacturing of high-quality mRNA. I have more than 9 year of experience in biochemistry and molecular biology, more specifically in cellular engineering and downstream processing. I am interesting in engineering cells to produce high-quality proteins and nucleic acids. I did my PhD in Biochemistry at the University of Oxford, UK.